Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vimta LabsBOM:524394 +3.58%84 EBITDA Margin % is 37.70% as of Jun. 2026, which is 33% above its 10-year median of 28.41. GuruFocus rates BOM:524394 with a GF Score™ of 84/100 and a GF Value™ of ₹495.16 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 203 Medical Diagnostics & Research companies, Vimta Labs ranks better than 96.55% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Vimta Labs's EBITDA for the
three
months ended in Jun. 2026 was ₹411 Mil. Vimta Labs's Revenue for the
three
months ended in Jun. 2026 was ₹1,091 Mil. Therefore, Vimta Labs's EBITDA margin for the quarter that ended in Jun. 2026 was 37.70%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Vimta Labs EBITDA Margin % Related Terms
Vimta Labs EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Vimta Labs's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524394 vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Vimta Labs's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vimta Labs EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Vimta Labs's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Vimta Labs's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vimta Labs (BOM:524394) has a EBITDA Margin % of 37.70% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Vimta Labs and its competitors. This is 33% above median its historical median of 28.41. Over the past decade, Vimta Labs' EBITDA Margin % has ranged from 17.74 to 36.91. According to the industry distribution chart, Vimta Labs ranks #7 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 3.4%.
Is Vimta Labs' EBITDA Margin % too high?
Vimta Labs' current EBITDA Margin % of 37.70% is 33% above median its 10-year median of 28.41. Over the past 10 years, this metric has ranged from a low of 17.74 to a high of 36.91. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.43. Vimta Labs' value of 37.70% is 594.3% above this industry median. Based on the distribution chart, Vimta Labs ranks #7 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Vimta Labs has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vimta Labs' EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Vimta Labs ranks #7 out of 203 companies for EBITDA Margin %. This places Vimta Labs in the top 3% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 5.43. Vimta Labs' value of 37.70% is 594.3% above this benchmark. Historically, Vimta Labs' own EBITDA Margin % has ranged from 17.74 to 36.91 over the past decade. While the company's 10-year median is 28.41 vs. the industry median of 5.43, Vimta Labs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.43, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vimta Labs's current EBITDA Margin % of 37.70% is 594.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Vimta Labs and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vimta Labs's current EBITDA Margin % is 37.70%, which is 33% above median its own 10-year median of 28.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vimta Labs stock overvalued right now?
Based on GuruFocus' analysis, Vimta Labs (BOM:524394) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹495.16, compared to a current price of ₹641.20 — trading 29.5% above its estimated fair value. The current EBITDA Margin % is 37.70%, which is 33% above median its 10-year median of 28.41 and 594.3% above the Medical Diagnostics & Research industry median of 5.43. Vimta Labs' overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Vimta Labs (BOM:524394), the current EBITDA Margin % is 37.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vimta Labs (BOM:524394) Overvalued in 2026?
Based on GuruFocus' analysis, Vimta Labs stock appears to be overvalued.
The current stock price of ₹641.20 is trading 29.5% above its estimated GF Value™ of ₹495.16.
GuruFocus considers Vimta Labs to be Modestly Overvalued.
Key valuation signals for BOM:524394:
EBITDA Margin %: 37.70% (33% above median its 10-year median of 28.41)
GF Value™: ₹495.16 vs. price of ₹641.20 (29.5% above fair value)
Industry Position: 594.3% above the Medical Diagnostics & Research median (#7 of 203)
No single metric tells the full story. See the BOM:524394 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vimta Labs Ltd is a comprehensive contract research and testing organization, providing a wide range of services to pharmaceutical, biopharmaceutical, food, consumer goods, electronic, electrical, agrochemical, healthcare, medical device, and many other industries. Its services portfolio includes testing and contract research services in the fields of clinical research, pre-clinical research, clinical diagnostics, biopharma services, analytical testing, research and environmental studies, and Others. It has only one reportable segment namely Contract Research and Testing Services which generates the revenue.
84GF Score
Get the complete analysis for BOM:524394
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524394 has been successfully added to your 
